Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential vs. combined therapy results from a MOSG randomized phase III trial.

被引：0
|
作者：
Soto, C. [1 ]
Torrecillas, L. [1 ]
Reyes, S. [1 ]
Ramirez, M. [1 ]
Perez, L. [1 ]
Cervantes, G. [1 ]
Gonzalez, F. [1 ]
Tellez, E. [1 ]
Cortes, P. [1 ]
Benitez, H. [1 ]
机构：
[1] ISSSTE, IMSS, Mexico City, DF, Mexico
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：20S / 20S
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
    Daigo Yamamoto
    Nobuaki Sato
    Yoshiaki Rai
    Yutaka Yamamoto
    Mitsue Saito
    Hiroji Iwata
    Norikazu Masuda
    Shoji Oura
    Junichiro Watanabe
    Satoshi Hattori
    Yoshimasa Matsuura
    Katsumasa Kuroi
    Breast Cancer Research and Treatment, 2017, 161 : 473 - 482
  • [22] Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes - Preliminary Results of a Multicentric Phase II Trial in Egypt
    Kandil, A.
    Hamada, E.
    Moawad, M.
    El Arab, L. Ezz
    Metwalli, H.
    Bathiouny, M.
    Mourad, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S351 - S351
  • [23] A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer
    Pallis, A. G.
    Boukovinas, I.
    Ardavanis, A.
    Varthalitis, I.
    Malamos, N.
    Georgoulias, V.
    Mavroudis, D.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1164 - 1169
  • [24] Capecitabine (X) combined with trastuzumab (H) as first-line therapy in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC)
    Xu, Ligong
    Song, Santai
    Zhu, Jianxin
    Luo, Rongcheng
    Li, Lejing
    Jiao, Shunchang
    Pan, Hongming
    Tao, Ming
    Su, Yongqian
    Liu, Duanqi
    ANNALS OF ONCOLOGY, 2004, 15 : 38 - 38
  • [25] Gemcitabine (G) plus capecitabine (C) in previously treated metastatic breast cancer (MBC) patients.: Final results from a phase II GOTI trial.
    Pérez-Manga, G
    López-Criado, P
    Méndez, M
    Quiben, R
    Palomero, I
    Sancho, JF
    Belón, J
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S205 - S206
  • [26] A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results
    Besse-Hammer, T.
    Villanueva, C.
    Campone, M.
    Machiels, J.
    Awada, A.
    Magherini, E.
    Dubin, F.
    Semiond, D.
    Pivot, X. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy
    Vahdat, L. T.
    Twelves, C.
    Allison, M. K.
    Cortes, J. A.
    Campone, M.
    Shuster, D. E.
    Wanders, J.
    Fang, F.
    Gurnani, R. D.
    Blum, J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC)
    Barrios, C.
    Liu, M-C
    Lee, S. C.
    Vanlemmens, L.
    Ferrero, J-M
    Tabei, T.
    Pivot, X.
    Iwata, H.
    Aogi, K.
    Brickman, M.
    Zhang, K.
    Kern, K.
    Martin, M.
    CANCER RESEARCH, 2009, 69 (24) : 497S - 497S
  • [29] Neoadjuvant capecitabine chemoradiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy: findings from a prospective phase II trial.
    Gaui, M
    Amorim, G
    Pereira, G
    Moreira, D
    Djahjah, C
    Spector, N
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S227 - S227
  • [30] Positive efficacy results of the X-ACT phase III trial of capecitabine (X) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes' C colon cancer
    McKendrick, Joseph
    Cassidy, James
    Van Hazel, Guy
    Twelves, Chris
    Wong, Alfred
    Nowacki, Marek
    Kroning, Hendrik
    Cervantes, Andres
    Herrmann, Richard
    Burris, Howard, III
    ANNALS OF ONCOLOGY, 2004, 15 : 73 - 74
12345